Oxidative/nitrosative stress and the pathobiology of chronic obstructive pulmonary disease

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 3, 2013, Pages 580-588

  Pandey, Rajesh ^a   Singh, Mamta ^b   Singhal, Udita ^b   Gupta, Krishna Bihari ^c   Aggarwal, Surendra Kumar ^d  

^a MAHARISHI MARKANDESHWAR INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

^b PDM Dental College and Research Institute   (India)

^c POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^d MM University   (India)

Author keywords

Antioxidants; COPD; Inflammatory response; Nitrosative stress; Oxidative stress; Smoking

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; HYDROXYL RADICAL; LONG ACTING DRUG; MUCOLYTIC AGENT; OXYGEN; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SHORT ACTING DRUG; STEROID; TOBACCO SMOKE;

AIR POLLUTANT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; LUNG INFECTION; LUNG INJURY; MORTALITY; MUCUS SECRETION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SMOKING CESSATION; SMOKING HABIT;

EID: 84874879375     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/4360.2832     Document Type: Review

References (68)

1. Celli BR, Mac Nee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-946.
2. American Thoracic Society, European Respiratory Society ATS/ERS recommendations for standardized procedures for the online and offine measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005; 171: 912-930.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163: 1256-1276.
4. Wright JL. Emphysema: concepts under change - a pathologist's perspective. Mod Patho. 1995; l8: 873-880.
5. Fletcher C, Peto R. The natural history of chronic airfow obstruction. Br Med J. 1997; 1: 1645-1648.
6. Kim WD, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities. Am Rev Respir Dis. 1991; 144: 1385-1390.
7. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925-931.
8. Anthonisen NR, Manfreda J, Warren CP, Hershfeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196-204.
9. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet. 2003; 362: 1053-1061. GOLD (2010) Global Initiative for Chronic Obstructive Lung Disease (GOLD).
10. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest. 2003; 123: 1684-1692.
11. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez M V, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005; 366: 1875-1881.
12. Bano R, Ahmad N, Mahagaonkar AM, Latti RG. Study of lung functions in smokers and non-smokers in rural India. Indian J Physiol Pharmacol. 2011; 55: 84-88.
13. Maitra A, Kumar V. The lung and the upper respiratory tract. In: Kumar V, Cotran RS, Robbins SL, Eds. Robbins Basic Pathology, 7th edition, Saunders (Reed Elsevier India Pvt. Ltd.), New Delhi, 2003; 453-508.
14. Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D et al. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci. 2006; 48: 23-29.
15. Peto R. Smoking and death: The past 40 years and the next 40. BMJ. 1994; 309: 937-940.
16. Snider G. Chronic obstructive pulmonary disease: risk factors, patho-physiology and pathogenesis. Annu Rev Med. 1989; 40: 411-429.
17. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandstrom T, Larsson K. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003; 97: 115-122.
18. Kotaniemi JT, Pallasaho P, Sovijarvi AR, Laitinen LA, Lundback B. Respiratory symptoms and asthma in relation to cold climate, inhaled allergens, and irritants: a comparison between northern and southern Finland. J Asthma. 2003; 39: 649-658.
19. Koyama H, Geddes DM. Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Thorax. 1998; 53 (Suppl): 10S-14S.
20. Johnson P, Balakrishnan K, Ramaswamy P, Ghosh S, Sadhasivam M, Abirami O. Prevalence of chronic obstructive pulmonary disease in rural women of Tamilnadu: implications for refning disease burden assessments attributable to household biomass combustion. Glob Health Action. 2011; 4: 26-72.
21. Marvisi M, Civardi G. Chronic obstructive pulmonary disease beyond cigarette smoke. Respiration. 2005; 72: 575-576.
22. Oberley-Deegan RE, Regan EA, Kinnula VL, Crapo JD. Extracellular superoxide dismutase and risk of COPD. COPD. 2009; 6: 307-312.
23. Montes de Oca M, Halbert RJ, Lopez MV, Perez-Padilla R, Tálamo C, Moreno D et al. Chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. EurRespir J. 2012 Jan 26[Epub ahead of print, PMID:22282547].
24. Clarke PBS. Tobacco smoking, genes, and dopamine. Lancet. 1998; 352: 84-85.
25. Lakhdar R, Denden S, Kassab A, Leban N, Knani J, Lefranc G. Update in chronic obstructive pulmonary disease: role of antioxidant and metabolizing gene polymorphisms. Exp Lung Res. 2011; 37: 364-375.
26. Zhang RB, He QY, Yang RH, Lu BB, Liu YJ. Study on matrix metalloproteinase 1, 9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han nationality in northern China. Zhonghua Liu Xing Bing Xue Za Zhi. 2005; 26: 907-910.
27. Lee YL, Chen W, Tsai WK, Lee JC, Chiou HL, Shih CM et al. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med. 2006; 147: 228-233.
28. Knoell DL, Ralston DR, Coulter KR, Wewers MD. α1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1β, and tumor necrosis factor-α in monocytes. Am J Respir Crit Care Med. 1998; 157: 246-255.
29. Senior RM, Anthonisen NR. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 1998; 157 (Suppl): S139-S147.
30. Hoidal JR, McCusker KT, Marshall BC, Rao NV. Oxidative damage and COPD. In: Cherniack NS, Ed. Chronic Obstructive Pulmonary Disease, 1st edition, WB Saunders, Philadelphia, 1991; 44-49.
31. Halliwell B and Gutteridge JMC: Oxidative stress; in Free radicals in biology and medicine, Halliwell B and Gutteridge JMC eds, 3rd ED, Oxford University Press, Oxford University Press, New York, 1999;246-350.
32. Pandey R, Gupta S, Lal H, Mehta HC, Aggarwal SK. Hyper-homocysteinemia and cardiovascular disease: the nutritional perspectives. Indian J ClinBiochem. 2000; 15 (Suppl): 20-30.
33. Eiserich J P, van der Vliet A, Handelman GJ, Halliwell B, Cross CE. Dietary antioxidants and cigarette smoke-induced biomolecular damage: a complex interaction. Am J Clin Nutr. 1995; 62 (Suppl):1490S-1500S.
34. Rahman I, Mac Nee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax. 1996; 51: 348-350.
35. Owen CA. Proteinase and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 373-385.
36. Isik B, Isik RS, Ceylan A, Calik O. Trace elements and oxidative stress in chronic obstructive pulmonary disease. Saudi Med J. 2005; 26: 1882-1885.
37. Ciencewicki J, Trivedi S, Kleeberger SR. Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol. 2008; 122: 456-468.
38. Harju T, Kaarteenaho-Wiik R, Soini Y, Sormunen R, Kinnula VL. Diminished immune reactivity of gamma-glutamylcysteine synthetase in the airways of smokers' lung. Am J Respir Crit Care Med. 2002;166: 754-759.
39. Aoshiba K, Zhou F, Tsuji T, Nagai A. DNA damage as a molecular link in the pathogenesis of COPD in smokers. Eur Respir J. 2012 Jan 20 [Epub ahead of print, PMID:22267761].
40. Sugiura H, Ichinose M. Nitrative stress in infammatory lung diseases. Nitric Oxide. 2011; 25: 138-144.
41. Travis J. Oxidants and antioxidants in the lung. Am Rev Respir Dis. 1987; 135: 773-774.
42. Stoian I, Oros A, Moldoveanu E. Apoptosis and free radicals. Biochem Mol Med. 1996; 59: 93-97.
43. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and infammation. Int J Chron Obstruct Pulmon Dis. 2011; 6: 413-421.
44. Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys. 2005; 43: 167-188.
45. MacNee W, Selby C. New perspectives on basic mechanisms in lung disease 2- Neutrophil traffc in the lungs: role of hemodynamics, cell adhesion, and deformability. Thorax. 1993; 48: 79-88.
46. Christman JW, Sadikot R T, Blackwell TS. The role of nuclear factor-κB in pulmonary diseases. Chest. 2000; 117: 1482-1487.
47. rd edition, Oxford University Press, Oxford, 1996; 2616-2628.
48. Van der Strate BWA, Postma DS, Brandsma C-A, Melgert BN, Luinge MA, Geerlings M. Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med. 2006; 173: 751-758.
49. Belai Y, Hernandez-Juviel JM, Bruni R, Waring AJ, Walther FJ. Addition of alpha1-antitrypsin to surfactant improves oxygenation in surfactant deficient rats. Am J Respir Crit Care Med. 1999; 159: 917-923.
50. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3: 245-251.
51. Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011; 8: 356-362.
52. Chevion S, Chevion M. Antioxidant status and human health: Use of cyclic voltammetry for the evaluation of the antioxidant capacity of plasma and of edible plants. In: Chiueh CC, Ed. Reactive Oxygen Species: From Radiation to Molecular Biology, New York Academy of Sciences, New York, 2000; 308-325.
53. Nicks ME, O'Brien MM, Bowler R P. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. COPD. 2011; 8: 264-269.
54. Morley JN, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. Am J ClinNutr. 2006; 83: 735-743.
55. Deneke SM, Fanburg BL. Normobaric oxygen toxicity of the lung. N Engl J Med. 1980; 303: 76-86.
56. Jackson RM. Pulmonary oxygen toxicity. Chest. 1985; 88: 900-905.
57. Skold CM, Liu X, Umino T. Human neutrophil elastase augments fbroblast-mediated contraction of released collagen gels. Am J Respir Crit Care Med. 1999; 159: 1138-1146.
58. Pride NB, Stockley RA. Chronic obstructive pulmonary disease. In: Weatherall DJ, Ledingham JGC, Warrel DA, Eds. Oxford Textbook of Medicine, 3rd edition, Oxford University Press, Oxford, 1996; 2766-2779.
59. Calverley PMA. Smoking cessation: professional problem or public policy? Respir Med. 1996; 90: 123-125.
60. Molfno NA. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration. 2005; 72: 105-112.
61. Houben JM, Mercken EM, Ketelslegers HB, Bast A, Wouters EF, Hageman GJ. Telomere shortening in chronic obstructive pulmonary disease. Respir Med. 2009; 103: 230-236.
62. Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen-radical-mediated component of reperfusion injury:reduction by recombinant human superoxide dismutase administered at the time of refow. Circulation. 1987; 75: 282-291.
63. Tanaka K, Tanaka Y, Miyazaki Y, Namba T, Sato K, Aoshiba K et al. Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. J Pharmacol Exp Ther. 2011; 338: 810-818.
64. Whiteley G, Kienle A, Lee S, Taylor P, Schofeld D, Braganza J. Micro-nutrient antioxidant therapy in the non-surgical management of chronic pancreatitis: long-term observations. Pancreas. 1994; 9: A807.
65. Grievink L, Smit HA, Ocke MC, van't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax.1998; 53: 166-171.
66. Gillisen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med. 1998; 92: 609-623.
67. Xu J, Li T, Wu H, Xu T. Role of thioredoxin in lung disease. Pulm Pharmacol Ther. 2012 Jan 25[Epub ahead of print, PMID:22293327].
68. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 2011 Nov 9 [Epub ahead of print, PMID:22101076.